Identification of HDAC9 as a viable therapeutic target for the treatment of gastric cancer

Histone deacetylase inhibitors (HDACis) are a new class of anticancer drugs confirmed to have good therapeutic effects against gastric cancer (GC) in preclinical experiments, but most HDACis are non-selective (pan-HDACis), with highly toxic side effects. Therefore, it is necessary to screen HDAC fam...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiong, Kai, Zhang, Hejun, Du, Yang, Tian, Jie, Ding, Shigang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802628/
https://www.ncbi.nlm.nih.gov/pubmed/31451695
http://dx.doi.org/10.1038/s12276-019-0301-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802628/
https://www.ncbi.nlm.nih.gov/pubmed/31451695
http://dx.doi.org/10.1038/s12276-019-0301-8

Ejemplares similares